-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Short Interest in PURE Bioscience, Inc. (OTCMKTS:PURE) Grows By 23.0%
Short Interest in PURE Bioscience, Inc. (OTCMKTS:PURE) Grows By 23.0%
PURE Bioscience, Inc. (OTCMKTS:PURE – Get Rating) was the target of a large growth in short interest in August. As of August 31st, there was short interest totalling 36,400 shares, a growth of 23.0% from the August 15th total of 29,600 shares. Based on an average trading volume of 190,100 shares, the short-interest ratio is presently 0.2 days.
PURE Bioscience Price Performance
PURE stock remained flat at $0.23 during mid-day trading on Friday. 10,600 shares of the company's stock were exchanged, compared to its average volume of 164,655. The business has a 50 day moving average of $0.21 and a 200 day moving average of $0.20. PURE Bioscience has a twelve month low of $0.15 and a twelve month high of $0.43.
Get PURE Bioscience alerts:PURE Bioscience (OTCMKTS:PURE – Get Rating) last issued its earnings results on Tuesday, June 14th. The company reported ($0.01) EPS for the quarter. The company had revenue of $0.50 million during the quarter. PURE Bioscience had a negative return on equity of 131.39% and a negative net margin of 131.59%.
PURE Bioscience Company Profile
(Get Rating)PURE Bioscience, Inc develops and commercializes antimicrobial products that provide solutions to the health and environmental challenges of pathogen and hygienic control in the United States and internationally. The company manufactures and distributes silver dihydrogen citrate (SDC), a non-toxic antimicrobial agent, which offers residual protection, as well as formulates with other compounds.
Featured Articles
- Get a free copy of the StockNews.com research report on PURE Bioscience (PURE)
- 3 Banks Worth Considering For Q4
- Stock Market: 3 Islands Of Strength In A Sea Of Red
- Is There a Cure for What is Ailing Teladoc Stock?
- No One Told These 3 Stocks It's a Down Week
- MarketBeat: Week in Review 9/12 – 9/16
Receive News & Ratings for PURE Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PURE Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.
PURE Bioscience, Inc. (OTCMKTS:PURE – Get Rating) was the target of a large growth in short interest in August. As of August 31st, there was short interest totalling 36,400 shares, a growth of 23.0% from the August 15th total of 29,600 shares. Based on an average trading volume of 190,100 shares, the short-interest ratio is presently 0.2 days.
Pure Bioscience,Inc.(场外交易平台:Pure-Get Rating)是8月份空头股数大幅增长的目标。截至8月31日,空头股数共有36,400股,较8月15日的29,600股增长23.0%。以190,100股的平均成交量计算,目前短息比为0.2天。
PURE Bioscience Price Performance
纯生物科学性价比
PURE stock remained flat at $0.23 during mid-day trading on Friday. 10,600 shares of the company's stock were exchanged, compared to its average volume of 164,655. The business has a 50 day moving average of $0.21 and a 200 day moving average of $0.20. PURE Bioscience has a twelve month low of $0.15 and a twelve month high of $0.43.
在周五午盘交易中,纯股票持平于0.23美元。该公司股票成交量为10,600股,而其平均成交量为164,655股。该业务的50日移动均线切入位在0.21美元,200日移动均线切入位在0.20美元。Pure Bioscience的12个月低点为0.15美元,12个月高位为0.43美元。
PURE Bioscience (OTCMKTS:PURE – Get Rating) last issued its earnings results on Tuesday, June 14th. The company reported ($0.01) EPS for the quarter. The company had revenue of $0.50 million during the quarter. PURE Bioscience had a negative return on equity of 131.39% and a negative net margin of 131.59%.
Pure Bioscience(OTCMKTS:Pure-Get Rating)最近一次发布财报是在6月14日(星期二)。该公司公布了该季度每股收益(0.01美元)。该公司本季度的收入为50万美元。纯生物科学公司的净资产回报率为负131.39%,净利润率为负131.59%。
PURE Bioscience Company Profile
Pure Bioscience公司简介
PURE Bioscience, Inc develops and commercializes antimicrobial products that provide solutions to the health and environmental challenges of pathogen and hygienic control in the United States and internationally. The company manufactures and distributes silver dihydrogen citrate (SDC), a non-toxic antimicrobial agent, which offers residual protection, as well as formulates with other compounds.
Pure Bioscience公司开发和商业化抗菌产品,为美国和国际上病原体的健康和环境挑战以及卫生控制提供解决方案。该公司制造和分销柠檬酸二氢银(SDC),这是一种无毒的抗菌剂,可提供残留保护,并与其他化合物一起配制。
Featured Articles
专题文章
- Get a free copy of the StockNews.com research report on PURE Bioscience (PURE)
- 3 Banks Worth Considering For Q4
- Stock Market: 3 Islands Of Strength In A Sea Of Red
- Is There a Cure for What is Ailing Teladoc Stock?
- No One Told These 3 Stocks It's a Down Week
- MarketBeat: Week in Review 9/12 – 9/16
- 免费获取StockNews.com关于纯生物科学的研究报告(PURE)
- 第四季度值得考虑的3家银行
- 股市:红海中的三座强国
- 有什么办法可以治愈Teladoc股票的问题吗?
- 没有人告诉这三只股票这是下跌的一周
- MarketBeat:回顾一周9/12-9/16
Receive News & Ratings for PURE Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PURE Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.
获得《纯生物科学日报》的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯接收对Pure Bioscience和相关公司的最新新闻和分析师评级的每日简要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧